

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 41509

Manuscript Type: Letter to the Editor

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors

Yu Sunakawa, Hironaga Satake, Wataru Ichikawa

Abstract

A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only

right-sided metastatic colorectal cancer (mCRC) compared with FOLFOXIRI plus

Match Overview

1	Crossref 25 words C Cremolini, C Antoniotti, S Lonardi, F Bergamo et al. "Primary tumor sidedness and benefit from FOLFOXIRI plus	2%
2	Crossref 21 words Y. Sunakawa, A. Tsuji, M. Fujii, W. Ichikawa. "No benefit ... om the addition of anti-EGFR antibody in all right-sided	2%
3	Crossref 19 words Yu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, Wu Zh ang et al. "Tumor sidedness and enriched gene groups ...	2%
4	Crossref 18 words Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, Masato Nakamura et al. "A phase II trial of 1st-line modified-FOL	2%
5	Crossref 14 words C Cremolini, C Antoniotti, S Lonardi, F Bergamo et al. "Pr imary Tumor Sidedness and Benefit from FOLFOXIRI p ...	1%
6	Crossref 13 words James J. Lee. "What Is the Best Systemic Therapy for L ... t-sided RAS Wild-type Metastatic Colorectal Cancer?", C	1%

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 6,910 条结果 (用时 0.59 秒)

Google 学术 : Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors

... spread and prognosis in metastatic colorectal cancer - Tran - 被引用次数 : 339

... tumour location in patients with metastatic colorectal ... - Holch - 被引用次数 : 132

... in patients with metastatic colorectal cancer - Boisen - 被引用次数 : 72

Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet ...

<https://www.karger.com/Article/FullText/492508> - 翻译此页

作者 : L Shui - 2018

2018年8月9日 - Keywords: FolfoxiriBevacizumabColorectal cancerConversion therapyR0 resection ...

Evidence indicated that the resection of metastases had significant survival ... Considering the FOLFOXIRI-Bev regimen could be associated with plus Bev regimen for patients with RAS wild-type right-sided tumors for ...

Primary Tumor Sidedness and Benefit from FOLFOXIRI plus ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29897402> - 翻译此页

作者 : C Cremolini - 2018 - 被引用次数 : 2 - 相关文章

2018年4月20日 - Background: Right-sided metastatic colorectal cancer (mCRC) patients have poor ... oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab.

缺少字词 : considering

Should FOLFOXIRI Plus Bevacizumab Be the Standard ... - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350810/> ▼ 翻译此页

作者 : RD Nipp - 2015 - 被引用次数 : 6 - 相关文章

2015年2月6日 - The majority of patients with metastatic colorectal cancer cannot be cured and ... When considering whether FOLFOXIRI/bevacizumab is the optimal ... Notably, more patients in the



Considering FOLFOXIRI plus bevacizumab for metastatic colorectal can



全部

新闻

图片

购物

地图

更多

设置

工具

找到约 6,460 条结果 (用时 0.46 秒)

Google 学术 : Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors

... spread and prognosis in metastatic colorectal cancer - Tran - 被引用次数 : 332

... tumour location in patients with metastatic colorectal ... - Holch - 被引用次数 : 104

... in patients with metastatic colorectal cancer - Boisen - 被引用次数 : 67

Primary Tumor Sidedness and Benefit from FOLFOXIRI plus ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29897402> - 翻译此页

作者 : C Cremolini - 2018 - 被引用次数 : 1 - 相关文章

2018年4月20日 - Background: Right-sided metastatic colorectal cancer (mCRC) patients have poor ... oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab.

缺少字词 : considering

Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350810/> - 翻译此页

作者 : RD Nipp - 2015 - 被引用次数 : 5 - 相关文章

2015年2月6日 - The majority of patients with metastatic colorectal cancer cannot be cured and ... When considering whether FOLFOXIRI/bevacizumab is the optimal ... Notably, more patients in the experimental arm had right-sided tumors.

[PDF] Primary tumor sidedness and benefit from FOLFOXIRI plus ...

gonogroup.org/.../Cremolini-et-al_Primary-sidedness-TRIBE_AnnOnc18.pd... - 翻译此页

作者 : C Cremolini - 被引用次数 : 1 - 相关文章

2018年4月20日 - Background: Right-sided metastatic colorectal cancer (mCRC) patients ... colorectal cancer, primary sidedness, FOLFOXIRI plus bevacizumab, RAS and ... anti-EGFR agents [7], thus

[全部](#) [新闻](#) [图片](#) [购物](#) [地图](#) [更多](#)[设置](#) [工具](#)

找到约 7,120 条结果 (用时 0.42 秒)

Google 学术 : Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors

... spread and prognosis in metastatic colorectal cancer - Tran - 被引用次数 : 339

... tumour location in patients with metastatic colorectal ... - Holch - 被引用次数 : 128

... in patients with metastatic colorectal cancer - Boisen - 被引用次数 : 72

Primary Tumor Sidedness and Benefit from FOLFOXIRI plus ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29897402> - 翻译此页

作者 : C Cremolini - 2018 - 被引用次数 : 2 - 相关文章

2018年4月20日 - Background: Right-sided metastatic colorectal cancer (mCRC) patients have poor ... oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab.

缺少字词 : considering

Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet ...

<https://www.karger.com/Article/FullText/492508> - 翻译此页

作者 : L Shui - 2018

2018年8月9日 - Keywords: FolfoxiriBevacizumabColorectal cancerConversion therapyR0 resection ... Evidence indicated that the resection of metastases had significant survival ... Considering the FOLFOXIRI-Bev regimen could be associated with plus Bev regimen for patients with RAS wild-type right-sided tumors for ...

[PDF] Primary tumor sidedness and benefit from FOLFOXIRI plus ...

gonogroup.org/.../Cremolini-et-al_Primary-sidedness-TRIBE_AnnOnc18.pdf ... 翻译此页